208 related articles for article (PubMed ID: 20628002)
1. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin-mediated cyclin D1 expression and Rb phosphorylation.
Chen W; Luo Y; Liu L; Zhou H; Xu B; Han X; Shen T; Liu Z; Lu Y; Huang S
Cancer Prev Res (Phila); 2010 Aug; 3(8):1015-25. PubMed ID: 20628002
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
3. Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer.
Pan Y; Shi J; Ni W; Liu Y; Wang S; Wang X; Wei Z; Wang A; Chen W; Lu Y
J Cell Mol Med; 2017 Sep; 21(9):2129-2139. PubMed ID: 28272775
[TBL] [Abstract][Full Text] [Related]
4. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM; Mita A; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096
[TBL] [Abstract][Full Text] [Related]
5. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
6. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E.
Ge Y; Cheng R; Zhou Y; Shen J; Peng L; Xu X; Dai Q; Liu P; Wang H; Ma X; Jia J; Chen Z
Mol Cell Biochem; 2012 Sep; 368(1-2):17-25. PubMed ID: 22614784
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
Chang WL; Hsu LC; Leu WJ; Chen CS; Guh JH
Oncotarget; 2015 Nov; 6(37):39806-20. PubMed ID: 26447757
[TBL] [Abstract][Full Text] [Related]
9. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
10. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Paternot S; Roger PP
Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
[TBL] [Abstract][Full Text] [Related]
12. Carbon monoxide releasing molecule-2 CORM-2 represses global protein synthesis by inhibition of eukaryotic elongation factor eEF2.
Schwer CI; Stoll P; Rospert S; Fitzke E; Schallner N; Bürkle H; Schmidt R; Humar M
Int J Biochem Cell Biol; 2013 Feb; 45(2):201-12. PubMed ID: 23041477
[TBL] [Abstract][Full Text] [Related]
13. mTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators.
Nader GA; McLoughlin TJ; Esser KA
Am J Physiol Cell Physiol; 2005 Dec; 289(6):C1457-65. PubMed ID: 16079186
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells.
MacManus CF; Pettigrew J; Seaton A; Wilson C; Maxwell PJ; Berlingeri S; Purcell C; McGurk M; Johnston PG; Waugh DJ
Mol Cancer Res; 2007 Jul; 5(7):737-48. PubMed ID: 17606477
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM; Mita A; Rowinsky EK
Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi M; Liu F; Tavorath R; Rosen N
Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PI3K/AKT molecular pathway mediated by membrane estrogen receptor GPER accounts for cryptotanshinone induced antiproliferative effect on breast cancer SKBR-3 cells.
Shi D; Zhao P; Cui L; Li H; Sun L; Niu J; Chen M
BMC Pharmacol Toxicol; 2020 May; 21(1):32. PubMed ID: 32357920
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
19. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
20. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation.
Mukhopadhyay A; Banerjee S; Stafford LJ; Xia C; Liu M; Aggarwal BB
Oncogene; 2002 Dec; 21(57):8852-61. PubMed ID: 12483537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
